CLINICAL QUESTION
In patients with atrial fibrillation and a high risk of stroke or bleeding, is left atrial appendage closure noninferior to best medical therapy (generally with a direct oral anticoagulant [DOAC])?
BOTTOM LINE
In patients with atrial fibrillation at high risk for major bleeding and stroke, best medical therapy (usually with a DOAC) is superior to left atrial appendage closure. The high cost of DOACs in the United States is a significant barrier for many patients. (Level of Evidence = 1b)
SYNOPSIS
Left atrial appendage closure is an alternative to DOACs in patients with atrial fibrillation and has been shown to be equivalent or superior to DOACs following catheter ablation and in patients undergoing cardiac surgery. In the German study, researchers identified patients with atrial fibrillation and a high risk of stroke (CHA2DS2-VASc [congestive heart failure, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 years, sex (female)] score ≥ 2), high risk of bleeding (HAS-BLED [hypertension, abnormal kidney and liver function, stroke, bleeding risk, labile international normalized ratio, elderly (older than 65 years), drug and alcohol use] score ≥ 3), a history of major bleeding, or chronic kidney disease. At baseline, the 888 patients had a mean age of 78 years, 39% were female, 93.5% were White, 43% had a history of major bleeding, and 24% had chronic kidney disease. Groups were balanced, and analysis was by intention to treat. The primary outcome was a composite of stroke, systemic embolism, major bleeding, or cardiovascular or unexplained death adjudicated by a committee masked to the treatment assignment. Patients were randomized to receive left atrial appendage closure with one of three devices chosen by the physician (93% of these patients received a device) or best medical therapy (85% received a DOAC, 3% a vitamin K antagonist, 2.3% antiplatelet therapy, and 9.5% received no therapy or had missing information). In the device implantation group, dual antiplatelet therapy was recommended for 3 months. The median follow-up was 3 years, and the longest follow-up was 6.7 years.
The composite outcome occurred significantly more often in the left atrial appendage closure group (16.8 vs 13.3 events per 100 person-years; number needed to treat [NNT] = 29) in the primary intention-to-treat analysis and in the per-protocol analysis for only those patients who received the device or anti-thrombotic therapy (16.6 vs 12.5; NNT = 24). This was primarily driven by more major bleeding and more cardiovascular or unexplained deaths. All-cause mortality was not significantly higher (14.8% vs 13.5%). Hospitalization for bleeding or a cardiovascular event was significantly more common in the device group (53.0 vs 39.4 events per 100 person-years; NNT = 7).
Study Design: Randomized controlled trial (single-blinded)
Funding Source: Government
Allocation: Concealed
Setting: Outpatient (specialty)
Reference: Landmesser U, Skurk C, Kirchhof P, et al.; CLOSURE-AF Trial Investigators. Left atrial appendage closure or medical therapy in atrial fibrillation. N Engl J Med. 2026;394(13):1270-1280.
Editor’s Note: Dr. Ebell is cofounder and editor-in-chief of Essential Evidence Plus.
Read the full article
Get immediate access, anytime, anywhere.
Choose a single article, issue, or full-access subscription.
Earn up to 14 CME credits per issue.
